

## Dear friends,

It is our pleasure to share our news with you.

This month was fruitful for us.

The phase I clinical trial of the drug PAM-9 "Radio- and Chemoprotector, Adjuvant of Radio- and Chemotherapy" have completed (both clinical and pharmacokinetic parts). The single-dose administration of the drug in the studied doses of 5 mg and 50 mg had no negative impact on the organs and systems of the clinical trial participants, attesting thus the drug's high safety and tolerability. PAM-9 is therefore recommended for further study of its efficacy in patients. For the moment, the phase II clinical study of PAM-9 is planned. The drug will be tested in patients suffering from cancer.

The permission of the Ministry of Health of the Russian Federation is expected for phase Ib clinical study of PAM-8 "Drug for the Recovery of Reproductive Function".



On May 23<sup>rd</sup> an awarding ceremony "Development Award - 2014" was held at the St. Petersburg International Economic Forum. The award, established by Russian Vnesheconombank ("Bank for Development and Foreign Economic Affairs"), was granted to laureates for their contribution to sustainable socio-economic development of Russia.

The project "Development and marketing of innovative products - immunochromatographic test strips for diagnosis of the myocardial infarction on the basis of heart-type fatty acid binding protein" implemented by the company "OFK Cardio" (a resident of the Alliance of Competences "Park of Active Molecules"), won the award for "The <u>BestProjectofSmallandMedium-SizedEnterprises</u>", beating 98 contenders.

"CARD-INFO" is a test system designed for diagnosis of myocardial infarction at early stages of its

development, when other diagnosis methods are inefficient. Immunoassay «CARD-INFO» is based on detecting H-FABP (heart-type fatty acid binding protein) in capillary blood. H-FABP is an early marker of myocardial damage. Its concentration in blood is significantly increased within 1,5-3 hours after myocardial ischemia symptom onset. The analysis requires several drops of capillary blood from fingertip, making the test system available for use in medical institutions, as well as individually at home. The "CARD-INFO" test system is included in the Register of Innovative Products, Technologies and



Services recommended for use in the Russian Federation (assigning №146). It was awarded with a gold medal in the category "Medicine of the Future" within an innovation contest of Russian manufacturers (at the IV International Forum on Intellectual Property "Expopriority-2012")

The project PAM-12 "Drug for Memory Recovery and Consolidation" was full with activities this month. We will be happy to provide you with more information about this project in our next letter.

Sincerely yours, Roziev R.